Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

Efficacy and safety of insulin glargine 300 units/mL in older people

Care of Older People – August 2018 digest.
A summary of the SENIOR trial comparing insulin glargine 300 units/mL and 100 units/mL in older people with type 2 diabetes.

Ritzel R, Harris SB, Baron H et al (2018) A randomized controlled trial comparing efficacy and safety of insulin glargine 300 units/mL versus 100 units/mL in older people with type 2 diabetes: results from the SENIOR study. Diabetes Care 41: 1672–80

  • SENIOR was a multicenter, phase 3b, open-label, randomised controlled trial comparing insulin glargine 300 units/mL (Gla-300) and 100 units/mL (Gla-100) in older people (age ≥65 years) with type 2 diabetes.
  • In total, 1014 participants, including a subgroup of 241 people aged ≥75 years, were randomised to one of the two glargine preparations. Insulin doses were adjusted regularly to achieve a self-monitored plasma glucose target of 5.0–7.2 mmol/L.
  • After 6 months of treatment, mean HbA1c was reduced from 66 to 56 mmol/mol (8.2% to 7.3%) in both treatment groups, with Gla-300 meeting its primary non-inferiority endpoint. Similar findings were observed in the ≥75-year-old subgroup.
  • Overall, there was no significant difference in rates of the secondary endpoint of confirmed or severe hypoglycaemia between the treatment groups (59% vs 62.7% in the Gla-300 and Gla-100 groups, respectively), although a trend toward lower rates with Gla-300 was observed at the lower hypoglycaemia threshold of <3.0 mmol/L.
  • In the ≥75-year-old subgroup, in general the rates of hypoglycaemia were similar to that of the overall cohort; however, the incidence of documented symptomatic hypoglycaemia (<3.0 mmol/L) was significantly lower in the Gla-300 group (1.5% vs 10.4%; relative risk, 0.33; 95% confidence interval, 0.12–0.88).
  • This study is limited by its open-label design and the relatively small number of hypoglycaemic events that occurred.

Click here to read the article in full.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.